Skip to main content

Advertisement

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner

Fig. 3

Dose and time dependence of cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin (CTLA-4-Ig)-mediated blockade of autoantibody-mediated cytokine production. Levels of interleukin (IL)-6 and IL-1β were measured in the supernatants of monocytes stimulated with 100 μg/ml anticitrullinated protein antibody (ACPA) immune complexes. Upper graphs: Time response. Abatacept (CTLA-4-Ig; red) or adalimumab (tumor necrosis factor antibody [TNF-Ab]; black) was added either 1 h before addition of ACPA (−1 h); at the time of ACPA challenge (0 h); or 1, 3, or 6 h after ACPA challenge. Lower graphs: Dose response. Different doses (1 ng, 10 ng, 100 ng, 1 μg, 10 μg, and 100 μg) of abatacept or adalimumab were added to the cultures. **p < 0.05, *** p < 0.01

Back to article page